Navigation Links
Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
Date:4/28/2010

SAN FRANCISCO, April 28 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today expanded its board of directors with the appointment of Paul B. Cleveland, executive vice president of corporate development and chief financial officer of Affymax, Inc.  

"With JX-594 entering Phase 3 trials for the treatment of liver cancer by the end of this year and a strong pipeline of novel clinical-stage products behind it, we believe Paul's superior financial acumen and strategic business insight will add important perspective to our board as we evaluate financing and partnering opportunities for optimal growth on our path to commercialization," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

Mr. Cleveland brings over 20 years of experience in strategic corporate transactions and investment banking to the Jennerex board. As executive vice president of corporate development and chief financial officer for Affymax, he manages all business development, strategic planning, financial and legal activities. Prior to Affymax, he served as managing director of the investment banks Integrated Finance, Ltd. and J.P. Morgan Chase and Co. (formerly Hambrecht & Quist), leading healthcare and technology mergers and acquisitions for the firms. Prior to his tenure in investment banking, he was a partner at Cooley Godward LLP. Mr. Cleveland serves as a member of the board of directors of Sangamo BioSciences, Inc.  He holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.

"Paul will be an excellent complement to Jennerex's board of directors, and we welcome him to our team.  His depth of experience will add significant value as we make strategic business decisions going forward," stated Brennan Mulcahy, chairman of the board of Jennerex.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
2. Jennerex Closes $5 Million First Tranche of Series C Financing
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
5. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. Biotech Industry Showing Resilience Despite Challenging Conditions
8. Global Jatrophaworld Training 2010... Set to Create and Build a Sustainable Biodiesel Industry
9. HealthTalker Adds Industry Expert Collie Turner to Its Executive Team
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):